All In Biotech

Drug Trial Radar · NCT06488664

An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

Multicenter International Single-blind Randomized Comparative Clinical Study of the Efficacy and Safety of GNR-068 (45 mg) and Stelara® (45 mg) and Assessment of the Safety, Tolerability and Long-term Effectiveness of GNR-068 in Patients With Moderate and Severe Forms of Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 422 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

422

Actual

Start

Jul 25, 2023

Primary completion

Apr 30, 2025

Study completion Nov 26, 2025

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Jul 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized single-blind comparative parallel group efficacy and safety study of ustekinumab biosimilar GNR-068 (45 mg) and reference product Stelara® (45 mg) in the treatment of patients with moderate and severe forms of plaque psoriasis. Participants received a subcutaneous dose of ustekinumab 45 mg (GNR-068 or Stelara®) at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg. For patients with partially respond to the initial regimen the regimen can be adjusted.

Conditions

  • Plaque Psoriasis

Interventions

  • GNR-068Biological

    GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.

  • Stelara®Biological

    Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with Psoriasis Area and Severity Index (PASI) Score of 75 Percent or AboveTime frame: Week 12

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation

    Barnaul, Barnaul, Russia

  • State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"

    Chelyabinsk, Chelyabinsk Oblast, Russia

  • Limited Liability Company "Ecology of Health"

    Chelyabinsk, Chelyabinsk Oblast, Russia

  • State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"

    Yekaterinburg, Ekaterinburg, Russia

  • Limited Liability Company "Alliance Biomedical - Ural Group"

    Izhevsk, Izhevsk, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation (FSBEI HE Kirov State Medical University of the Ministry of Health of Russia))

    Kirov, Kirov Oblast, Russia

  • Limited Liability Company "Available Polyclinic"

    Murino, Leningradskaya Oblast', Russia

  • State health care institution "Regional Dermatovenerological Dispensary"

    Lipetsk, Lipetsk Oblast, Russia

  • Limited Liability Company "OLLA-MED"

    Moscow, Moscow, Russia

  • Federal State Budgetary Institution "Research Institute of Rheumatology named after V.A. Nasonova"

    Moscow, Moscow, Russia

  • Limited Liability Company "Firma ORIS"

    Moscow, Moscow, Russia

  • State budgetary healthcare institution of the city of Moscow "Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Health Department"

    Moscow, Moscow, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of the Russian Federation (FSBEI HE "Russian University of Medicine" of the Ministry of Health of Russia)

    Moscow, Moscow, Russia

  • State budgetary healthcare institution of the Moscow region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"

    Moscow, Moscow, Russia

  • Limited Liability Company "Family Clinic No. 4"

    Korolyov, Moscow Oblast, Russia

  • Limited Liability Company "Medical Center "Healthy Family"

    Novosibirsk, Novosibirsk Oblast, Russia

  • Federal State Budgetary Educational Institution of Higher Education Orenburg State Medical University of the Ministry of Health of Russia

    Orenburg, Orenburg Oblast, Russia

  • State budgetary institution of the Ryazan region "Regional clinical dermatovenerological dispensary"

    Ryazan, Ryazan Oblast, Russia

  • Limited Liability Company "Clinic of Skin Diseases Pierre Wolkenstein"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "International Medical Center"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Medical Technologies" LLC "Medical Technologies"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Health Energy"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Interleukin"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Institute of Medical Research"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Research Center Eco-Safety"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "PiterKlinika"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "ArsVite North-West"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "Curator"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Private medical institution "Euromedservice"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "MEDINET"

    Saint Petersburg, Sankt-Peterburg, Russia

  • Limited Liability Company "SB Clinic of Cosmetology"

    Saratov, Saratov Oblast, Russia

  • Regional state budgetary healthcare institution "Smolensk Dermatovenerological Dispensary"

    Smolensk, Smolensk Oblast, Russia

  • Limited Liability Company Medical Center "Azbuka Health"

    Kazan', Tatarstan Republic, Russia

  • State Budgetary Healthcare Institution Ulyanovsk area Clinical Hospital

    Ulyanovsk, Ulyanovsk Oblast, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.